From the Stanford University lab of a cancer immunotherapy pioneer to an IPO, a small-but-growing Peninsula biotech company is looking to continue its win streak with its third biopharma collaboration of the year. Bolt Biotherapeutics Inc. of Redwood City said it will partner with drug giant Bristol-Myers Squibb Co. on a new combination of two […]

Cyclacel Pharmaceuticals recently announced the first patient dosed in its Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors and aggressive lymphomas. The trial used a streamlined study design and will determine the recommended Phase 2 dose. Once established, the trial will immediately enter a proof of concept, cohort stage trial with […]

A cell replacement therapy that uses retinal pigment epithelium-derived stem cells is showing the potential to restore retinal tissue in advanced age-related macular degeneration with geographic atrophy. “When we designed the trial, our aim was to stop or slow down the progression of geographic atrophy (GA), and much to our surprise, we found that this […]